Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ESG206
- Development stage
- Phase 2
- Lead developer
- Shanghai Escugen Biotechnology
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ESG206 is a recombinant humanized monoclonal antibody targeting the B-cell activating factor receptor (BAFFR; also known as tumor necrosis factor receptor superfamily member 13C or TNFRSF13C). It has been glycoengineered to enhance antibody-dependent cellular cytotoxicity (ADCC) effects. The drug is being developed primarily for the treatment of relapsed or refractory B-cell malignancies, including cases resistant to CD19 or CD20-targeted therapies such as rituximab and ibrutinib. Preclinical studies have demonstrated antitumor activity in various malignant B cell disease models. Clinical development includes phase I/II trials for indications such as B-cell lymphoma and idiopathic thrombocytopenic purpura[1][2][3][4].
- Other names
- anti-BAFFR monoclonal antibody ESG206
02
Targets
TNFRSF13C (B-cell Activating Factor Receptor)
Beyond the preview
Go deeper on ESG206.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ESG206.